NLM Digital Collections

Search

Start Over Subjects Antibodies, Monoclonal, Humanized ✖Remove constraint Subjects: Antibodies, Monoclonal, Humanized Publication Year 2000 to 2024 ✖Remove constraint Publication Year: <span class="from" data-blrl-begin="2000">2000</span> to <span class="to" data-blrl-end="2024">2024</span>

2. Belimumab and voclosporin for lupus nephritis: effectiveness and value : final report

Author(s):
Tice, Jeffrey A., author
Agboola, Foluso, author
Herron-Smith, Serina, author
Chapman, Rick, (Of Institute for Clinical and Economic Review), author
Pearson, Steven D., author
Mandrik, Olena, author
Thokala, P. (Praveen), author
Fotheringham, James, (Of University of Sheffield), author
Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, April 16, 2021
Subject(s):
Antibodies, Monoclonal, Humanized
B-Cell Activating Factor -- antagonists & inhibitors
Calcineurin Inhibitors -- therapeutic use
Cyclosporine -- therapeutic use
Immunosuppressive Agents -- therapeutic use
Lupus Nephritis -- drug therapy
Treatment Outcome
United States

3. Lecanemab for early Alzheimer’s disease: final evidence report

Author(s):
Lin, Grace A., author
Whittington, Melanie D., author
Wright, Abigail, (Of Institute for Clinical and Economic Review), author
Agboola, Foluso, author
Herron-Smith, Serina, author
Pearson, Steven D., author
Rind, David, (Of Institute for Clinical and Economic Review), author
Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, April 17, 2023
Subject(s):
Alzheimer Disease -- drug therapy
Antibodies, Monoclonal, Humanized
United States

4. Gene therapy for hemophilia B and an update on gene therapy for hemophilia A: effectiveness and value : final evidence report

Author(s):
Tice, Jeffrey A., author
Chu, Janet N., author
Moradi, Ashton, author
Herce-Hagiwara, Belen, author
Fahim, Shahariar Mohammed, author
Agboola, Foluso, author
Pearson, Steven D., author
Rind, David M., author
Walton, Surrey M., author
Sarker, Jyotirmoy, author
Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, December 22, 2022
Subject(s):
Antibodies, Bispecific
Antibodies, Monoclonal, Humanized
Cost-Effectiveness Analysis
Genetic Therapy
Hemophilia A -- therapy
Hemophilia B -- therapy
United States